NCT01680198View on ClinicalTrials.gov

Paricalcitol and Endothelial Function in Chronic Kidney Disease Patients (the PENNY Study)

PHASE3CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Chronic Kidney Disease.
Interventions
DRUG

Paracalcitol

Patients in the experimental arm received 2 micrograms Paricalcitol capsules daily, for 12 weeks. This dose was adjusted based on clinical laboratory parameters and the maximum dose was 2 micrograms daily.

DRUG

placebo

Trial Locations (1)

89124

Nephrology, Dialysis and Transplantation Unit, Reggio Calabria

All Listed Sponsors
lead

"Fondazione C.N.R./Regione Toscana G. Monasterio, Pisa, Italy"

OTHER_GOV

NCT01680198 - Paricalcitol and Endothelial Function in Chronic Kidney Disease Patients (the PENNY Study) | Biotech Hunter | Biotech Hunter